Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/172122
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLosa, F.-
dc.contributor.authorIglesias, L.-
dc.contributor.authorPané, M.-
dc.contributor.authorSanz, J.-
dc.contributor.authorNieto, B.-
dc.contributor.authorFusté, V.-
dc.contributor.authorCruz Merino, L. de la-
dc.contributor.authorConcha, Ángel-
dc.contributor.authorBalaña, Carmen-
dc.contributor.authorMatias-Guiu, Xavier-
dc.date.accessioned2020-11-17T08:15:24Z-
dc.date.available2020-11-17T08:15:24Z-
dc.date.issued2018-11-01-
dc.identifier.urihttp://hdl.handle.net/2445/172122-
dc.description.abstractCancer of unknown primary (CUP) is defined as a heterogeneous group of tumours that present with metastasis, and in which attempts to identify the original site have failed. They differ from other primary tumours in their biological features and how they spread, which means that they can be considered a separate entity. There are several hypotheses regarding their origin, but the most plausible explanation for their aggressiveness and chemoresistance seems to involve chromosomal instability. Depending on the type of study done, CUP can account for 2-9% of all cancer patients, mostly 60-75years old. This article reviews the main clinical, pathological, and molecular studies conducted to analyse and determine the origin of CUP. The main strategies for patient management and treatment, by both clinicians and pathologists, are also addressed.-
dc.format.extent11 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherSpringer International Publishing Ag-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1007/s12094-018-1899-z-
dc.relation.ispartofClinical & Translational Oncology, 2018, vol. 20, num. 11, p. 1361-1372-
dc.relation.urihttps://doi.org/10.1007/s12094-018-1899-z-
dc.rightscc by (c) Losa et al., 2018-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/-
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationCàncer-
dc.subject.classificationMetàstasi-
dc.subject.otherCancer-
dc.subject.otherMetastasis-
dc.title2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2020-11-11T17:38:51Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid29808414-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
LosaF.pdf1.15 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons